



New Advance in MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in Diseases

Guest Editor:

Dr. Lucia Natarelli

Institute for Cardiovascular
Prevention (IPEK), Ludwig-
Maximilians University,
Pettenkoferstr. 9, 80336 Munich,
Germany

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editor

Dear Colleagues,

Indeed, canonical ncRNAs and non-canonical ncRNAs, such as circular RNAs, miRtrons, isomiRs, and miRNA-like ncRNAs increase the spectra of action and versatility of the ncRNA family. Since ncRNAs are stable and easily detectable in biological fluids, ncRNAs have been investigated as promising diagnostic and therapeutic markers in cardiovascular and metabolic diseases. Nevertheless, recent findings indicate that miRNAs and lncRNAs can exert novel adaptive functions, such as miRNAs interacting with transcript factors and circRNAs released to activate the inflammation. Hence, ncRNAs can potentially be involved in clinical applications.

This Special Issue is dedicated to research articles and reviews regarding miRNA mechanisms when acting as regulators, biomarkers, and therapeutic targets in diseases.

Dr. Lucia Natarelli

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)